ALK and non-small cell lung carcinoma: Initially, first-generation TKIs such as gefitinib (for EGFR-positive NSCLC) and crizotinib (for EML4–ALK fusion-positive NSCLC) demonstrate strong anti-tumor activity; however, most patients develop resistance and subsequently relapse.